MHRA guidance on Supply and administration of Botox®, Vistabel®, Dysport® and other injectable medicines in cosmetic procedures

· Medicines and Healthcare products Regulatory Agency (MHRA)

As well as covering such questions as who can administer these medicines and who is an appropriate practitioner, this guidance refers to administration of these medicines under a Patient Group Direction (PGD) and the requirements for a valid PGD in the private sector.

The guidance also covers information for nurse independent prescribers and provides the Nursing and Midwifery Council’s position on the supply and administration of Botox® and other Injectable Medicines in Cosmetic Procedures.

Editors note January 2016 – whilst the MHRA information is hosted on MHRA archives, the MHRA has confirmed that these records remain relevant and in date.

Botulinum A toxinGuidance and GovernanceMedicines SafetyPatient Group DirectionsPolicy, Guidance, and StandardsRegulatory AdviceSystem Safety

Links